Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of its performance and prospects.

Shares of Lotus Eye Hospital & Institute Ltd surged to hit the upper circuit limit on 16 Mar 2026, reflecting robust buying interest and a significant daily price gain. The stock outperformed its sector and benchmark indices despite a micro-cap status and a recent downgrade in its mojo grade, signalling renewed investor enthusiasm in the hospital sector.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date perspective on its performance and outlook.

Shares of Lotus Eye Hospital & Institute Ltd surged to hit the upper circuit limit on 27 Feb 2026, propelled by robust buying interest and a significant intraday gain. The stock outperformed its sector and broader market indices, reflecting renewed investor confidence despite subdued delivery volumes and a micro-cap market capitalisation of ₹225 crores.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 23 Feb 2026, reflecting intense selling pressure and panic among investors. The stock closed at ₹112.88, down 3.94% on the day, marking a continuation of a sharp three-day decline that has wiped out over 13% of its value. This sudden drop underscores growing concerns about the company’s near-term prospects amid subdued investor participation and unfilled supply in the market.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 20 Feb 2026, succumbing to intense selling pressure that saw the stock lose 3.63% intraday and close near its lowest price of Rs 117.51. The hospital sector micro-cap, with a market capitalisation of Rs 257 crores, underperformed both its sector and the broader market, reflecting mounting investor concerns and a wave of panic selling.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with an up-to-date view of its performance and prospects.

Lotus Eye Hospital & Institute Ltd witnessed a significant surge in its share price on 19 Feb 2026, hitting the upper circuit limit of 5%, closing at ₹136.70. This marked the stock’s fourth consecutive day of gains, cumulatively rising 19.48%, driven by strong investor demand and heightened market participation despite a subdued broader hospital sector and Sensex performance.

Lotus Eye Hospital & Institute Ltd (NSE: 959118) surged to its upper circuit price limit on 18 Feb 2026, reflecting robust investor demand and sustained buying momentum. The stock closed at ₹128.60, marking a maximum daily gain of 4.97%, significantly outperforming its hospital sector peers and the broader market indices.

Lotus Eye Hospital & Institute Ltd witnessed robust buying interest on 17 Feb 2026, hitting its upper circuit limit with a 4.99% gain to close at ₹124.66. The stock outperformed its sector and benchmark indices, reflecting heightened investor enthusiasm and a surge in demand that remains unfilled due to regulatory price band restrictions.

Lotus Eye Hospital & Institute Ltd witnessed a robust surge in its share price on 16 Feb 2026, hitting the upper circuit limit of 5%, closing at ₹118.72. This sharp rally was driven by intense buying interest, a significant gap-up opening, and a notable reversal after two days of decline, signalling renewed investor confidence in this hospital sector micro-cap.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 13 Feb 2026, reflecting intense selling pressure and panic among investors. The stock closed at ₹113.34, down 5.53 points or 4.65% on the day, marking a maximum daily loss that capped further declines due to regulatory circuit filters.

Lotus Eye Hospital & Institute Ltd. reported a net loss of ₹0.26 crores for Q3 FY26 (October-December 2025), marking the second consecutive quarter of red ink and raising serious concerns about the micro-cap ophthalmology chain's operational viability. Despite posting its highest-ever quarterly revenue of ₹13.55 crores, the Coimbatore-based company continues to grapple with margin compression and profitability challenges that have eroded investor confidence.